Seelos Therapeutics inc (SEEL) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access SEEL Annual Balance Sheets →
Looking at balance sheet data from Seelos Therapeutics inc through Jun 30 2023 provides insight into Jun 30 2024's solvency and capital structure over time.
Quarterly Report, GAAP in USD millions
ITEM
(Jun 30 2024)
(Mar 31 2024) (Dec 31 2023) (Sep 30 2023) (Jun 30 2023)
Assets
Cash & cash equivalent0.29
Cash & Short-term Investments0.00
Accounts receivable0.19
Other Current Assets0.00
Prepaid Expense And Other Assets Current1.85
Total Current Assets2.33
Other Assets, Noncurrent0.05
Operating Lease Right Of Use Asset0.05
Total Assets2.38
Liabilities
Accounts Payable, Current AC15.69
Accrued Liabilities, Current AC4.36
Convertible Subordinated Debt, Current LO10.11
Other Liabilities, Current0.36
Total Current Liabilities30.51
Convertible Subordinated Debt, Noncurrent CO0.00
Total Long-term Debt0.00
Other liabilities, Noncurrent0.00
Operating Lease Liability Current0.05
Total Liabilities30.51
Stockholders' Equity
Common Stock Value0.00
Additional Paid In Capital Common Stock225.44
Retained Earnings / Accumulated Deficit-253.58
Other Equity0.00
Common Stockholder's Equity-28.13
Total Stockholder's Equity-28.13
Liabilities & Stockholder's Equity2.38
4 historic quarters locked

Sign in to unlock the full Seelos Therapeutics inc balance sheet history.

About Seelos Therapeutics Inc Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC 10-Q filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001410578-24-001435

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.